Thalidomide in Advanced Hepatocellular Carcinoma With Optional Low-Dose Interferon- 2a Upon Progression

Oncologist - United States
doi 10.1634/theoncologist.10-9-718
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Alphamed Press

Related search

Efficacy and Safety of Thalidomide in Patients With Hepatocellular Carcinoma

World Journal of Gastroenterology
MedicineGastroenterology
2006English

Post-Progression Survival and Progression-Free Survival in Patients With Advanced Hepatocellular Carcinoma Treated by Sorafenib

Hepatology Research
HepatologyInfectious Diseases
2015English

Successful Treatment of Extramedullary Tumors With Low-Dose Thalidomide in Patients With Multiple Myeloma

Internal Medicine
Internal MedicineMedicine
2010English

Improvement of Anaemia in Patients With Primary Myelofibrosis by Low-Dose Thalidomide and Prednisone

Acta medica (Hradec Kralove)
Medicine
2016English

New Systemic Treatments in Advanced Hepatocellular Carcinoma

Liver Transplantation
HepatologyTransplantationSurgery
2019English

High Dose Raloxifene in Patients With Advanced Breast Carcinoma

Breast Cancer Research
Cancer ResearchOncology
2000English

Association of Radiation Dose With Local Failure in Hepatocellular Carcinoma (HCC)

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2019English

Phase 2 Study of Lenvatinib in Patients With Advanced Hepatocellular Carcinoma

Journal of Gastroenterology
Gastroenterology
2016English

High Immunosuppressive Burden in Advanced Hepatocellular Carcinoma Patients

OncoImmunology
OncologyAllergyImmunology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy